11 October 2018 : Laboratory Research
Effects of Enhancer of Zeste Homolog 2 (EZH2) Expression on Brain Glioma Cell Proliferation and Tumorigenesis
Tianci Cheng1BDF, Yinghui Xu1ACEG*DOI: 10.12659/MSM.909814
Med Sci Monit 2018; 24: LBR7249-7255
Abstract
BACKGROUND: Brain glioma is a type of common primary intracranial malignant tumor, the prognosis of which is frequently unfavorable. Enhancer of zeste homolog 2 (EZH2) belongs to poly-sulfur protein family and can mediate cell proliferation and differentiation via the modulation of various genes expressions. In addition, it is further related with occurrence and metastasis of malignant tumors. This study investigated the effect of EZH2 expression on proliferation and tumorigenesis of brain glioma cells.
MATERIAL AND METHODS: Glioma tumor tissues were collected from 3 patients who received surgery, and the glioma stem cells were then separated, cultured, and identified by flow cytometry. RNA interference approach was used to suppress EZH2 expression, which was confirmed by quantitative real-time polymerase chain reaction (qRT-PCR). Clonal formation assay analyzed the change of cell proliferation potency. The effect on tumorigenesis potency of glioma stem cells was determined by mouse transplantation assay. Western blot investigated the effect of EZH2 on levels of oncogenes such as HER-2, c-myc, PI3K, and Akt.
RESULTS: Flow cytometry revealed cancer stem cells in glioma tissues took up 39.4%, and qRT-PCR showed that EZH2 expression was decreased by 72% after the treatment of RNA interference in glioma cells (P<0.05). Both cell clonal formation and xenograft assays showed that the downregulation of EZH2 inhibited glioma cell proliferation (P<0.05) and weakened tumorigenesis potency (P<0.05). Western blot results showed that the reduction of EZH2 also suppressed expressions of oncogenes including c-myc and Akt (P<0.05).
CONCLUSIONS: Our data demonstrated that in brain glioma cells, the decrease of EZH2 level could suppress cell proliferation and tumorigenesis potency, and meanwhile inhibit the expressions of oncogenes including c-myc and Akt.
Keywords: Cells, Glioma
889 5
Editorial
01 September 2023 : Editorial
Editorial: A Rapid Global Increase in COVID-19 is Due to the Emergence of the EG.5 (Eris) Subvariant of Omicron SARS-CoV-2DOI: 10.12659/MSM.942244
Med Sci Monit 2023; 29:e942244
In Press
21 Sep 2023 : Clinical Research
The Impact of Implementing the Vortex Approach on Airway Management Performance in Stressed Medical Student...Med Sci Monit In Press; DOI: 10.12659/MSM.940372
20 Sep 2023 : Clinical Research
A Retrospective Study to Compare Pharyngeal Anatomical Changes Measured Before and After Treatment for Malo...Med Sci Monit In Press; DOI: 10.12659/MSM.941749
20 Sep 2023 : Database Analysis
Comparative Finite Element Analysis of Endocrowns and Traditional Restorations for Endodontically Treated M...Med Sci Monit In Press; DOI: 10.12659/MSM.941314
19 Sep 2023 : Laboratory Research
Comparative Evaluation of Dimensional (Vertical/Horizontal) and Occlusal Accuracy of Non-Working Antagonist...Med Sci Monit In Press; DOI: 10.12659/MSM.941654
Most Viewed Current Articles
13 Nov 2021 : Clinical Research
Acceptance of COVID-19 Vaccination and Its Associated Factors Among Cancer Patients Attending the Oncology ...DOI :10.12659/MSM.932788
Med Sci Monit 2021; 27:e932788
30 Dec 2021 : Clinical Research
Retrospective Study of Outcomes and Hospitalization Rates of Patients in Italy with a Confirmed Diagnosis o...DOI :10.12659/MSM.935379
Med Sci Monit 2021; 27:e935379
08 Mar 2022 : Review article
A Review of the Potential Roles of Antioxidant and Anti-Inflammatory Pharmacological Approaches for the Man...DOI :10.12659/MSM.936292
Med Sci Monit 2022; 28:e936292
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952